Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Marco Ruella, MD, Shannon L Maude, MD PhD, Boris Engels, PhD, David M. Barrett, Noelle Frey, MD, Katherine T Marcucci, PhD, Olga Shestova, PhD, Nathan Singh, MD, Jessica Perazzelli, PhD, David A Christian, PhD, Dana Haagen, BS, Simon F Lacey, PhD BS, J. Joseph Melenhorst, PhD, Jennifer Brogdon, PhD, Regina M Young, PhD, David L Porter, MD, Carl H June, MD, Stephan A Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2017) 130 (Supplement 1): 807.

https://doi.org/10.1182/blood.V130.Suppl_1.807.807

Published: 2017

Journal Articles

Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells

Katherine D Cummins, BMBS, Noelle Frey, MD, Anne Marie Nelson, Aliza Schmidt, MS, Selina Luger, MD FRCPC, Randi E. Isaacs, MD, Simon F Lacey, PhD BS, Elizabeth Hexner, MDMS, J. Joseph Melenhorst, PhD, Carl H June, MD, David L Porter, MD, Saar I Gill, MD PhD

Blood (2017) 130 (Supplement 1): 1359.

https://doi.org/10.1182/blood.V130.Suppl_1.1359.1359

Published: 2017

Journal Articles

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 1319.

https://doi.org/10.1182/blood.V130.Suppl_1.1319.1319

Published: 2017

Journal Articles

Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia

Joseph A. Fraietta, PhD, Simon F. Lacey, PhD, Nicholas S Wilcox, Felipe Bedoya, PhD, Fang Chen, PhD, Elena Orlando, PhD, Jennifer L Brogdon, PhD, Wei-Ting Hwang, PhD, Noelle Frey, MD MS, Regina M Young, PhD, Edward Pequignot, M.S., David E Ambrose, BS, Bruce L Levine, PhD, Hans Bitter, PhD, David L Porter, MD, Jun Xu, PhD, Carl H June, MD, Jan Joseph Melenhorst, PhD

Blood (2016) 128 (22): 57.

https://doi.org/10.1182/blood.V128.22.57.57

Published: 2016

Journal Articles

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma

Blood (2016) 128 (22): 974.

https://doi.org/10.1182/blood.V128.22.974.974

Published: 2016

Journal Articles

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 217.

https://doi.org/10.1182/blood.V128.22.217.217

Published: 2016

Journal Articles

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

Karen Thudium Mueller, PharmD, MS, Abhijit Chakraborty, PhD, Patricia A Wood, MD PhD, Rakesh Awasthi, BPharm, Alfonso Quintas-Cardama, MD, Xia Han, MS, Shannon L Maude, MD PhD, Stephan A. Grupp, MD PhD, David L Porter, MD, Noelle Frey, MD MS, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Jan J. Melenhorst, PhD, Carl H June, MD, Simon F. Lacey, PhD

Blood (2016) 128 (22): 220.

https://doi.org/10.1182/blood.V128.22.220.220

Published: 2016

Journal Articles

Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Simon F. Lacey, PhD, Pamela A Shaw, PhD, David T Teachey, MD, Scott L. Weiss, MD, Fang Chen, PhD, Vanessa E Gonzalez, M.B.A, Noelle Frey, MD MS, David L Porter, MD, Shannon L Maude, MD PhD, Stephan A Grupp, MD PhD, Edward Pequignot, M.S., Carl H June, MD, Jan J. Melenhorst, PhD

Blood (2016) 128 (22): 2812.

https://doi.org/10.1182/blood.V128.22.2812.2812

Published: 2016

Journal Articles

Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation

Clinton Yam, MBBS, Lisa Crisalli, BS, Selina Luger, MD, Alison Loren, MD MS, Elizabeth O Hexner, MD, Noelle Frey, MD, James Mangan, MD PhD, Amy Gao, MS, Edward A. Stadtmauer, MD, David Porter, MD, Ran Reshef, MD

Blood (2015) 126 (23): 4380.

https://doi.org/10.1182/blood.V126.23.4380.4380

Published: 2015

Journal Articles

Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Clinton Yam, MBBS, Daniel J. Landsburg, MD, Xinyi Lin, PhD, Anthony Mato, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Noelle Frey, MD, Edward A. Stadtmauer, MD, David Porter, MD, Stephen J. Schuster, MD, Sunita Dwivedy Nasta, MD

Blood (2015) 126 (23): 3183.

https://doi.org/10.1182/blood.V126.23.3183.3183

Published: 2015

Journal Articles

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Steven C Goldstein, MD, Selina M. Luger, MD, Noelle Frey, MD, Alexander Perl, MD, Edward A Stadtmauer, MD, Donald Tsai, MD, Alison Loren, MD, Sunita Nasta, MD, Elizabeth Hexner, MD, Ran Reshef, MD, Jacqueline Smith, CRNP, Joanne Hinkle, Pavel Vassilev, BS, Michael J Vozniak, PharmD, David L. Porter, MD

Blood (2010) 116 (21): 4519.

https://doi.org/10.1182/blood.V116.21.4519.4519

Published: 2010

Journal Articles

Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease

Courtney D. DiNardo, MD, Alison Loren, MD, Steven Goldstein, MD, Stephen J. Schuster, Alexander Perl, MD, Donald Tsai, MD, Noelle Frey, MD, Elizabeth Hexner, MD, Ran Reshef, MD, Edward A. Stadtmauer, MD, David L. Porter, MD, Selina Luger, MD

Blood (2010) 116 (21): 2366.

https://doi.org/10.1182/blood.V116.21.2366.2366

Published: 2010

Journal Articles

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

Alison Rager, MD, Steven C. Goldstein, MD, Noelle Frey, MD, Jennifer Davis, PharmD, Michael Vozniak, PharmD, Jacqueline Smith, Elizabeth Hexner, MD, Alison Wakoff Loren, MD, MS, Selina Luger, MD, Alexander Perl, MD, Ran Reshef, MD, Donald E Tsai, MD, PhD, Edward A. Stadtmauer, MD, David Porter, MD

Blood (2009) 114 (22): 4643.

https://doi.org/10.1182/blood.V114.22.4643.4643

Published: 2009

Journal Articles

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Steven C Goldstein, MD, Bruce Levine, PhD, Jacqueline Smith, MSN, CRNP, Joanne Hinkle, RN, BSN, OCN, Selina Luger, MD, Alexander Perl, MD, Alison Loren, MD, Noelle Frey, MD, Edward Stadtmauer, MD, Daniel Schullery, PhD, Jean Boyer, PhD, Dennis L. Confer, MD, David Porter, MD, Carl H. June, MD

Blood (2008) 112 (11): 468.

https://doi.org/10.1182/blood.V112.11.468.468

Published: 2008

Journal Articles

Rapid Transport and Infusion of Hematopoietic Stem Cells Can Improve Outcome after Unrelated Donor Transplant.

Hillard M. Lazarus, MD, Fangyu Kan, MS, Sergey Tarima, PhD, Richard E. Champlin, MD, Dennis Confer, MD, Noelle Frey, MD, Sergio Giralt, MD, John E. Wagner, MD, Mary M. Horowitz, MD, Mary Eapen, MBBS

Blood (2007) 110 (11): 3063.

https://doi.org/10.1182/blood.V110.11.3063.3063

Published: 2007

NARROW

Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models

Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells

Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma

Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia

Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)

Unrelated Donors Are Associated with Improved Relapse Free Survival Compared to Related Donors in Patients with Myelodysplastic Syndrome Undergoing Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation

Autologous Stem Cell Transplantation in First Complete Remission May Not Extend Progression Free Survival in Patients with ALK-Negative Peripheral T Cell Lymphoma

Reduced Intensity Conditioning with Fludarabine/Busulfan 6.4mg/Kg Results In High Donor Chimerism and Low Toxicity In Both Related and Unrelated Allo-SCT for Hematologic Malignancies.

Outcomes of Myeloablative Hematopoietic Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia with Relapsed or Refractory Disease

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

First Report of the Prophylactic Administration of Ex Vivo Co-Stimulated Donor Lymphocyte Infusion (DLI) from Related and Unrelated Donors after Reduced Intensity Conditioning for High Risk Hematologic Malignancies

Rapid Transport and Infusion of Hematopoietic Stem Cells Can Improve Outcome after Unrelated Donor Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only